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Simple Summary: Passive immunization with hyperimmune plasma from convalescent patients has
been proposed as a potentially useful treatment for COVID-19. Nevertheless, its efficacy in patients
with COVID-19 remains uncertain. Thus, the establishment and validation of standardized methods
that predict the viral neutralizing (VN) activity of plasma against SARS-CoV-2 is of utmost importance
to appraise its therapeutic value. Using an in-house quantitative ELISA test and two independent
cohorts with a total of 345 donors, we found that plasma and serum from most convalescent donors
contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2,
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with varying concentrations which correlate with previous disease severity and gender. Anti-
RBD IgG plasma concentration significantly correlated with the plasma/serum VN activity against
SARS-CoV-2 in vitro.
Abstract: Several hundred millions of people have been diagnosed of coronavirus disease 2019
(COVID-19), causing millions of deaths and a high socioeconomic burden. SARS-CoV-2, the causative
agent of COVID-19, induces both specific T- and B-cell responses, being antibodies against the
virus detected a few days after infection. Passive immunization with hyperimmune plasma from
convalescent patients has been proposed as a potentially useful treatment for COVID-19. Using an
in-house quantitative ELISA test, we found that plasma from 177 convalescent donors contained
IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, although at
very different concentrations which correlated with previous disease severity and gender. Anti-RBD
IgG plasma concentrations significantly correlated with the plasma viral neutralizing activity (VN)
against SARS-CoV-2 in vitro. Similar results were found using an independent cohort of serum from
168 convalescent health workers. These results validate an in-house RBD IgG ELISA test in a large
cohort of COVID-19 convalescent patients and indicate that plasma from all convalescent donors does
not contain a high enough amount of anti-SARS-CoV-2-RBD neutralizing IgG to prevent SARS-CoV-2
infection in vitro. The use of quantitative anti-RBD IgG detection systems might help to predict the
efficacy of the passive immunization using plasma from patients recovered from SARS-CoV-2.
Keywords: coronavirus; SARS-CoV-2; IgG; antibody; convalescent plasma; ELISA
1. Introduction
A new coronavirus responsible for severe acute respiratory syndrome (SARS), known
as SARS-CoV-2, emerged in Wuhan, China in 2019 [1,2] and spread rapidly to the rest
of the world. SARS-CoV-2 belongs to the family of human betacoronaviruses and it is
the third member identified in this family causing a severe respiratory disease, behind
the viruses SARS-CoV and Middle East respiratory syndrome (MERS) [3]. However, in
contrast to SARS-CoV and MERS, which caused infections restricted to a limited number
of countries, a few weeks after its identification SARS-CoV-2 had propagated all over the
world, originating the pandemic known as coronavirus disease 19 (COVID-19). Despite
the lethality of SARS-CoV-2 being significantly lower than that of SARS-CoV or MERS, the
rapid propagation of the virus, having already infected millions of people, has caused more
than half a million deaths and rising, a number far greater than that caused by SARS-CoV
and MERS. A large proportion of COVID-19 patients are asymptomatic, which seems to
facilitate viral spread. Among symptomatic patients, different stages of disease severity can
be found ranging from mild (mild symptoms) to critical (viral sepsis symptoms including
respiratory failure, shock, or multiorgan system dysfunction), with intermediate stages like
moderate or severe pneumonia [4,5].
The immune response against SARS-CoV-2 is characterized by the activation of spe-
cific T- and B-cell responses against different viral epitopes, some of which are shared by
SARS-CoV and seasonal coronaviruses [6–11]. In patients undergoing mild COVID-19 dis-
ease an efficient robust immune response characterized by the early activation of CD4+ T
and cytotoxic CD8+ T cells seems to contribute to viral control and attenuation of disease
progression [12,13]. In contrast, the early depletion of lymphocyte populations together with
aberrant T cell hyperactivation, T cell exhaustion, and an exacerbated inflammatory response
are the main features of the immune imbalance observed during severe COVID-19 [14,15].
Albeit huge efforts have been invested in developing effective treatments against
COVID-19, most molecules with direct antiviral activity that have been clinically tested
are showing limited efficacy [16]. Thus, the treatment of moderate, severe, and critical
COVID-19 is mostly focused on supplemental oxygen and anti-inflammatory therapy
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to treat/prevent pneumonia, acute respiratory distress syndrome (ARDS), and cytokine
release syndrome, the main events responsible for fatal outcomes [4,5].
As an alternative to synthetic and natural antiviral drugs, passive immunization has
been used since early 20th century to treat different viral infections including SARS-CoV
and MERS [17,18]. This old form of immunotherapy has emerged as one of the most
promising treatments for severe/critical COVID-19. Thus, albeit the clinical evidence of
efficacy and safety of convalescent plasma to treat COVID-19 was limited, due to the
emergency situation, emergency use authorization (EUA) was granted by the FDA (Food
and Drug Administration, US) to treat patients with severe disease and the first clinical trials
suggested that it might be beneficial for patients with moderate-to-severe acute respiratory
distress syndrome requiring a mechanical ventilation [19–21]. However, based on the
most recent available evidence that does not support a clear role of convalescent plasma in
patients with severe disease [22], the criteria has changed and EUA has been granted only
for high-titer convalescent plasma among hospitalized patients with COVID-19 who are
early in the disease course or have impaired humoral immunity.
Passive immunization consists of the transfer of pathogen-specific antibodies to pa-
tients whose immune system has not originated a response to control the infection [23]. In
this way, donors’ antibodies help to neutralize and attenuate pathogen replication while
the patient’s immune response activates to clear the infection. Among the different forms
of passive antibody transfer is the use of plasma from convalescent patients who have
recently recovered from an infection, which might be an effective and economic way to treat
severe infections. However, the efficacy of this therapy in patients with COVID-19 remains
controversial since both positive and negative results using convalescent plasma transfer
have been reported in COVID-19 [19,20,24–27]. An apparent lack of standardization in the
criteria used to select plasma with high neutralizing activity is one of the main problems
that need to be overcome to optimize this treatment and improve its efficacy [23]. As an
example of these limitations, a recent study found that the use of hyperimmune convales-
cent plasma was not beneficial for COVID-19 treatment. However, SARS-CoV-2-specific
antibodies were not determined in convalescent plasma donors [28].
In contrast to SARS and MERS, where antibodies are detected for 2–3 years after
infection [29,30], the duration of antibody titers in COVID-19 patients is still controversial.
However, recent studies show that spike-specific antibodies are detected in patients after
six months of recovery [31,32]. In addition, although antibodies against different viral
epitopes including spike (S), nucleoprotein (N), or membrane protein (M) are detected,
only those specific for spike may present therapeutic activity. Spike contains a receptor-
binding domain (RBD) that is the responsible for interacting with the membrane receptor
ACE2 allowing viral entry and cell infection. Thus, antibodies against RBD would present
neutralizing activity, since they would block spike-ACE2 interaction. RBD is a region that
seems to contain immunodominant epitopes against which antibodies are generated in
COVID-19 patients [33]. In addition, other spike regions like the N-terminal domain have
been shown to regulate its interaction with ACE2 and viral entry, thus also potentially
being a target for neutralizing antibodies [34]. Thus, the validation of fast and robust
methods to quantify the presence of neutralizing antibodies in plasma from COVID-19
convalescent patients is required in order to create plasma biobanks at hospitals in order
to ensure the greatest efficiency and maximum performance of passive immunization in
COVID-19.
Here, we have validated a previously developed in-house RBD IgG ELISA test [35]
using a large cohort (more than 320 samples in total) of convalescent plasma and serum
samples and adapted it to quantify the concentration of plasma RBD IgG and its correlation
with the SARS-CoV-2 neutralizing activity in vitro.
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2. Materials and Methods
2.1. Expression and Purification of RBD
The optimized DNA sequence encoding amino acid residues 319–541 of the Receptor-
Binding Domain (RBD) was synthesized by Gen-Script (USA) for expression in HEK293
cells. The DNA, containing at the 5′-end a recognition sequence for KpnI, and at the
3′-end a stop codon and a recognition sequence for XhoI, was cloned into a modified
pHLSec containing after the secretion signal sequence a 12xHis tag, a superfolder Green
Fluorescent Protein (GFP) [36], and a tobacco etch virus (TEV) cleavage site, rendering
the vector pHLSec-12His-GFP-TEV-RBD. Both the synthesis of the RBD construct and the
engineered pHLSec together with the cloning of RBD into pHLSec-12His-GFP-TEV were
performed by GenScript. pHLSec-12His-GFP-TEV-RBD was transfected into an HEK293F
cell line (Thermo Fisher Scientific) as described below. Cells were grown in suspension
in a humidified 37 ◦C and 8% CO2 incubator with rotation at 125 rpm. Transfection was
performed at a cell density of 2.5 × 106 cell/mL in fresh F17 serum-free media with 2%
Glutamax and 0.1% P188. For each 150 mL of culture, 450 µg of the plasmid (1 µg/µL) was
diluted to 135 µL with sterilized 1.5 M NaCl. This mixture was added to each 150 mL cell
culture flask and incubated for 5 min in the incubator. After that, 1.35 mg of PEI-MAX
(1 mg/mL) was mixed to 135 µL with sterilized 1.5 M NaCl and added to the cell culture
flask. Cells were diluted 1:1 with pre-warmed media supplemented with valproic acid
24 h post-transfection to a final concentration of 2.2 mM. Cells were harvested 6 days
post-transfection by spinning down at 300× g for 5 min, after which the supernatants
were collected and centrifuged at 4000× g for 15 min. Supernatant was dialyzed against
buffer A (25 mM TRIS pH 7.5, 300 mM NaCl) and loaded into a His-Trap Column (GE
Healthcare). Protein was eluted with an imidazol gradient in buffer A from 10 mM up
to 500 mM. Buffer exchange to 25 mM TRIS pH 7.5, 150 mM NaCl (buffer B) was carried
out using a HiPrep 26/10 Desalting Column (GE Healthcare). TEV protease was then
added in a ratio 1:50 (TEV:RBD) to the fusion construct in order to cleavage the His-GFP.
After 20 h of reaction at 18 ◦C, the cleavage was satisfactorily verified through SDS-
PAGE. TEV protease and GFP were removed from the solution using a His-Trap Column
(GE Healthcare), and the RBD was collected from the flow-through. Quantification of
protein was carried out by absorbance at 280 nm using the theoretical extinction coefficient,
ε280 nm(RBD) = 33,350 M−1cm−1.
2.2. Human Samples
A total of 177 plasma samples were obtained from convalescent COVID-19 donors
from the Biobank of the Aragon Health System. Patients qualified for the study based
on the following criteria: (a) they were eligible for blood donation; (b) aged 18–55 years;
(c) they had received a COVID-19 diagnosis by a test to detect viral RNA (RT-qPCR) or
anti-SARS-CoV-2 antibodies; (d) they had one negative COVID-19 nasopharyngeal swab
tests based on RT-qPCR; (e) they had been discharged from the hospital or did not present
symptoms for more than two weeks; and (f) they did not present COVID-19 symptoms
at time of or prior to the donation of convalescent plasma. As an independent cohort,
168 human serum samples from convalescent COVID-19 health care professionals from
the Hospital Clinico Universitario Lozano Blesa were used. All samples were stored at
−80 ◦C until used for ELISA tests. A total of 40 human plasma and 30 human serum
samples from healthy donors collected before 2018 were used as the negative control
(pre-COVID-19 samples).
Samples and data from patients included in this study were provided by the Biobank of
the Aragon Health System (PT17/0015/0039), integrated in the Spanish National Biobanks
Network, and they were processed following standard operating procedures with the
appropriate approval of the relevant ethics and scientific committees.
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2.3. Determination of Anti-RBD IgG Levels by ELISA
An in-house indirect ELISA for the detection of IgG specific for RBD was established.
Ninety-six-well plates were coated overnight, at 4 ◦C with 100 ng RBD protein in PBS.
Subsequently, the coating solution was removed, and the plate was washed three times
with 200 µL per well of PBS + TWEEN 0.05% (wash buffer). Non-fat milk (3%) dissolved
in PBS + TWEEN 0.05% was used as blocking solution. The plate was incubated with a
blocking solution for 2 h at 37 ◦C. Serum or plasma samples were prepared in 1% non-fat
milk dissolved in PBS + TWEEN 0.05% (buffer assay). The blocking solution was removed
and 100 µL of serum or plasma samples were added per well. Samples were incubated for
1 h at 37 ◦C. All samples were run in duplicate. Next, the plates were washed five times with
200 µL of wash buffer and 100 µL of goat anti-human IgG-Fc horseradish peroxidase (HRP)
conjugate (1:300.000; Thermo Fisher Scientific) was added. After 1 h, plates were washed
seven times with the wash buffer and 100 µL of TMB (3,3′,5,5′-tetramethylbenzidine; Sigma–
Aldrich, St. Louis, MO, USA) solution was added to each well. The substrate was incubated
for 10 min and the reaction was stopped by the addition of 50 µL of 2 M sulfuric acid. The
optical density at 450 nm (OD450) was measured using a Multi-Mode Microplate Reader
(Synergy™ HT, BioTek, Winooski, VT, USA).
Background value was determined at OD450 in wells without RBDs. The corrected
OD450 values were calculated by subtracting the background value from the OD values in
RBD-coated wells.
In some cases, the concentration of IgG (mg/L) in serum or plasma samples was
quantified by regression analysis using a standard, serially diluted recombinant human
purified IgG (Thermo Fisher Scientific, Waltham, MA, USA).
The limit of detection (LOD) was calculated using human negative plasma samples
(collected before 2018) as mean + 3 × SD. LOD was used as the cutoff value to discriminate
between positive and negative samples. Sensitivity and specificity were calculated using
the 2 × 2 table method including the true positive, true negative, false positive, and false
negative values using plasma samples collected before 2018 and plasma samples from
convalescent donors.
Tests with the commercial ELISA assay (SARS-CoV-2 RBD IgG ELISA Kit; My-
BioSource) were performed according to the manufacturer’s instructions. Briefly, 100 µL of
samples and a blank control were added into their respective wells. Plates were covered
and incubated at room temperature for 1 h. The content of the wells was discarded. Plates
were washed 3 times with 300 µL of wash buffer. 100 µL of detection solution were added
to each well. Plates were incubated at room temperature for 1 h. After that time, plates
were washed four times with the wash buffer. Once completely dry, 100 µL of substrate
solution were added to each well. This substrate was left on the plates for 15 min and
then the reaction was stopped by the addition of 100 µL per well of stop solution. The
optical density at 450 nm (OD450) was measured using a Multi-Mode Microplate Reader
(Synergy™ HT, BioTek).
2.4. Virus Isolation and Expansion in Cell Culture
The epithelial cell line, Vero E6, from the kidney of a Cercopithecus aethiops, was kindly
provided by Júlia Vergara from the Centro de Investigación en Sanidad Animal IRTA-
CReSA (Barcelona, Spain). Vero E6 cells were cultured in Dulbecco’s Modified Eagle
Medium (Sigma) supplemented with 10% fetal bovine serum (FBS) (Sigma), 2 mM Gluta-
max (Gibco), 100 U/mL penicillin (Sigma), 100 µg/mL streptomycin (Sigma), 0.25 µg/mL
amphotericin B (Sigma), 1% non-essential amino acids (Gibco), and 25 mM HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid; Biowest), referred as complete medium
in T75 flasks for expansion, and kept at 37 ◦C, in a 5% CO2 humidified incubator. Com-
plete medium with 2% FBS, denominated growth medium, was used for titration and
neutralization tests.
SARS-CoV-2 virus was isolated from a COVID-19 patient at the Hospital Clínico
Lozano Blesa (Zaragoza, Spain). Virus identity was confirmed by real-time PCR, electron
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microscopy, and RNA sequencing and classified as B1.1 linage [37]. The virus was seeded
and passaged in Vero E6 cells to establish high-titer batches that were used in the neutral-
ization assays. Vero E6 cells were seeded in that T75 flasks at a density of 105 cells/mL in
complete medium and after 48–76 h, the sub-confluent cell monolayer was washed with
phosphate buffered saline (PBS). Cells were then infected with 1–2 mL of growth medium
containing the virus. After one hour of incubation at 37 ◦C (with gentle shaking every
10 min), 10 mL of growth medium were added. The flasks were observed daily and the
virus was harvested 76 h later, when a cytopathic effect (CPE) of 80–90% was visible. The
culture medium was centrifuged at 4 ◦C, 1000× g for 5 min to remove the cell debris. Then
the virus was concentrated using Lenti-X Concentrator (Clontech Laboratories) by mixing
1 volume of Lenti-X Concentrator with 3 volumes of the clarified supernatant and mixing
by gentle inversion. The mixture was incubated for 30 min at 4 ◦C and then centrifuged
at 1500× g for 45 min at 4 ◦C. The supernatant was carefully removed and the pellet was
resuspended in 1 mL of growth medium. Samples were aliquoted and stored at −80 ◦C.
2.5. SARS-CoV-2 Titration
The virus was titrated in serial 1 log dilutions to obtain the 50% tissue culture infectious
dose (TCID50) per mL using VERO-E6 cultures in 96-well plates. 104 cells/well were seeded
the day before the titration and the neutralization assays. The supernatant was discarded
and 100 µL of the virus serial dilutions in growth medium were added to the wells. The
plates were observed daily for a total of 72–96 h for the presence of virus CPE using an
inverted optical microscope. The 50% endpoint titers were calculated according to the
Ramakrishnan simple formula based on eight replicates per point for titration [38] using
the Ramakrishan newly proposed method formula: log10 50% endpoint dilution = ((total
number of wells with CPE/number of wells per dilution) + 0.5) × log dilution factor.
2.6. Micro-Neutralization Assay
Serum and plasma samples were heat-inactivated for 30 min at 56 ◦C and two-fold
serial dilutions, starting from 1:10, were performed and mixed with an equal volume of
SARS-CoV-2 diluted in growth medium. The serum/plasma-virus mixture was incubated
for 1 h at 37 ◦C and 5% CO2, and afterwards 500 TCID50 of SARS-CoV-2 were added
by duplicate to a 96-well plate containing a semi-confluent Vero E6 monolayer whose
supernatant had been previously discarded. Positive and negative controls using the virus
or serum/plasma alone, respectively, were used. Plates were incubated for 72–96 h at 37 ◦C
and 5% CO2.
CPE was studied using an inverted optical microscope and a colorimetric read-out
using crystal violet. The supernatant of each plate was carefully discarded and 100 µL of 4%
formaldehyde were added. After 1 h at room temperature, the formaldehyde was discarded
and 50 µL of 1% crystal violet in 20% methanol in water were added and incubated for
15 min at room temperature. Plates were washed twice in water and CPE was seen with
the naked eye or with an inverted microscope by trained operators. The neutralization titer
was calculated as the highest serum dilution that protected more than the 50% of cells from
CPE, taking into account that the starting dilution ratio of the serum to the cells was 1:20.
3. Results and Discussion
This study included 177 plasma donors that had recently recovered from COVID-
19. The main characteristics of these donors are summarized in Table 1. COVID-19 was
confirmed in all patients by at least a positive PCR test. The median age was 44 and
approximately half of the patients corresponded to each gender. The median time from the
onset of COVID-19 symptoms to donation was 44 days and 13.6% of the patients required
hospitalization who were categorized as having had moderate/severe COVID-19 (Table 1).
The rest of the clinical variables, such as fever or supplemental oxygen, are indicated
in Table 1. In this cohort we aimed to validate in a large number of samples a recently
developed indirect ELISA that employed recombinant RBD produced in mammalian cells
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as an immobilized antigen to quantify IgG against SARS-CoV-2 RBD in blood [35]. First
of all, we compared the results obtained with this in-house developed ELISA (in-house
RBD IgG ELISA) with those using a commercial ELISA (MyBiosource) that also detected
RBD IgG. As shown in Figure 1, the correlation between both ELISA tests was very good
confirming the efficacy of the in-house developed ELISA test to detect SARS-CoV-2 RBD-
specific IgG.
Table 1. Characteristics of convalescent plasma donors.
Age (Median; Range) 44 (20–64)
Gender (female) 92/177 (52%)
Asymptomatic 22/177 (12%)
Time from symptom onset (median; range) 45 (22–111)
Moderate/severe COVID-19 (hospitalization) 24/177 (13.6%)
Fever, non-hospitalized 47/153 (30.7%)
Oxygenation, hospitalized 11/24 (45.8%)
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ELISA and the one developed in-house in convalescent plasma samples. The presence of RBD
IgG was analyzed in plasma samples from convalescent COVID-19 patients (n = 177) by both a
commercial ELISA and one developed in-house, as described in materials and methods. Absorbance
values were represented and their correlation analyzed. Pearson r and P values (two-tailed) were
determined using GraphPad Prism 8.0.2.
Both the commercial and the previously described in-house ELISA tests [35] did not
quantify antibody concentrations, which would be important step in providing a robust
standardized protocol to optimize the use of plasma in passive immunization. Thus, we
used the in-house ELISA to establish a quantitative RBD IgG test, in which convalescent
plasma IgG concentration could be correlated with the plasma VN activity. To this aim, we
established a calibration curve employing purified human IgG and the anti-human IgG
secondary antibody employed as detection antibody in the in-house RBD IgG ELISA. Using
this curve, the limit of detection of human IgG was established as 1 ng/mL. The absorbance
values obtained in diluted plasma samples were extrapolated in the calibration curve and
the concentration of RBD IgG was calculated. We determined the limit of detection of the
RBD IgG ELISA test to establish a cutoff value in order to discriminate between positive
and negative samples. To this aim, we used 20 plasma samples from pre-COVID-19 healthy
donors that had been collected before 2018. The cutoff value was 80 ng/mL. A sample
was considered as positive when the concentration of IgG was higher than the cutoff.
Test sensitivity and specificity calculated using the pre-COVID-19 healthy donors and
the convalescent plasma samples were 72% and 100%, respectively. The sensitivity value,
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although good, is relatively low, which is likely due to the samples from patients that have
suffered from COVID-19 but have not generated IgG, which is known in COVID-19.
As shown in Figure 2A, all plasma samples from pre-COVID-19 healthy donors that
had been collected before 2018 tested negative for RBD IgG. Although the sample size is
relatively small (40) this result suggests that the RBD IgG ELISA test specifically detects IgG
against SARS-CoV-2 RBD, supporting a previous independent study employing 50 healthy
donors [35]. In contrast, 72% of plasma samples from COVID-19 convalescent patients were
positive for RBD IgG (Figure 2A). The minimum and maximum concentrations detected in
positive samples were 0.087 and 45 mg/L, respectively, and the mean concentration was
3.3 mg/L. However, as can be seen in Figure 2A, there was a great variability between the
concentrations detected in the different samples, with a standard deviation of six and a
coefficient of variation of 200%.
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Since more than half of convalescent plasma donors presented relatively low con-
centrations of RBD IgG in plasma (less than 1 mg/L), which may impact the efficacy
of passive immunization, we decided to analyze if disease severity, classified according
to the requirement for hospitalization, correlated with the concentration of plasma RBD
IgG. As shown in Figure 2B, the concentration of RBD IgG was significantly higher in the
convalescent patients who had required hospitalization than in those that were asymp-
tomatic or presented mild symptoms who did not require hospitalization. In addition, in
non-hospitalized patients, there were no differences between asymptomatic patients and
those that presented mild symptoms (Figure 2C). In contrast, non-hospitalized patients
with fever presented a significantly higher concentration of RBD IgG (Figure 2D). There
were not significant differences between patients that required admission to the intensive
care unit and those that did not (not shown), but hospitalized patients that required supple-
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mental oxygen presented higher levels of RBD IgG (Figure 2D). In addition, male patients
presented significantly higher levels of RBD IgG than female patients (Figure 2D).
These results indicate that the concentration of RBD IgG antibodies is increased in
patients that had recovered from COVID-19 and required hospitalization and also in
male patients and, thus, the application of this criterion might help to optimize donor
selection and to improve the efficiency of passive immunization protocols for COVID-19.
This finding is in line with previous studies indicating than moderate/severe cases of
COVID-19 present higher levels of anti-SARS-CoV-2 IgG antibodies, albeit, in contrast to
our study, most analyses were performed in hospitalized COVID-19 patients with active
infection [39,40]. Similarly to our results, recent studies employing fewer donors have
found that the presence of RBD IgG was higher in convalescent plasma from patients that
had presented persistent and/or high fever [41] or that had required hospitalization [42].
Thus, our study employing a greater number of convalescent plasma donors validates
these previous findings and, in addition, provides a novel quantitative test that might help
to standardize donor selection.
Next, we analyzed if the concentration of RBD IgG correlated with the VN activity
of plasma. To this aim, we selected plasma samples that contained different RBD IgG
concentrations so that we could establish a concentration of IgG that was able to predict
the VN of the plasma. VN activity was calculated as the plasma dilution that inactivated
50% of SARS-CoV-2 virus in cultures of Vero E6 cells, the so-called VN EC50 titer [38,43].
As shown in Figure 3A, the plasma concentration of RBD IgG correlated very well with
plasma VN activity. It was found that most plasma samples that contained more than
3 mg/L RBD IgG presented a VN EC50 titer higher than 1:100, meaning that a plasma
dilution of 1:100 inactivated 50% of the virus. We also calculated the plasma RBD IgG
concentrations that presented a VN EC50 of 1:80 and 1:160, the levels recommended by FDA
for the use of convalescent plasma for COVID-19 passive immunization, by using linear
regression analyses in Figure 3A, which were found to be 1.96 and 12 mg/L, respectively.
Based on these results samples were classified according to the RBD concentration as low
(less than 0.3 mg/L), medium (between 0.3 and 2 mg/L), and high (more than 2 mg/L),
finding that they grouped very well according to their VN activity (Figure 3B). Samples
from pre-COVID-19 healthy donors did not show any VN activity confirming that the
presence of antiviral activity in plasma from COVID-19 convalescent donors is specific for
SARS-CoV-2-infected individuals.
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Finally, we confirmed and expanded our results to other types of samples employing
a different patient cohort and using serum instead of plasma. Here, prospectively collected
serum samples from COVID-19 convalescent workers at the Hospital Clinico Lozano Blesa
were selected and the concentration of RBD IgG was calculated. As shown in Figure 4A,
serum from healthy donors collected before the emergence of COVID-19 did not present
RBD IgG, confirming the results found in plasma samples. In contrast, most COVID-19
convalescent serum samples (93%) were positive for RBD IgG with concentration values
ranging from 0.01 to 19 mg/L. The mean value of serum RBD IgG was 4.8 mg/L with a
standard deviation of 6.3 and a coefficient of variation of 129%. These results were similar
to those found in plasma samples, albeit they are not directly comparable since a donor
cohort was used. Like in plasma samples, serum samples grouped very well according to
the level of RBD IgG (Figure 4B) (where levels of less than 0.3, between 0.3 and 2, and more
than 2 mg/L classed as low, medium, and high respectively), and thus, the correlation
of serum RBD IgG concentration with VN EC50 titer was also very good (Figure 4C). It
should be noted that the VN activity of serum was in general lower than in plasma samples.
Serum samples with similar RBD IgG concentrations to plasma samples presented lower
values of VN EC50 titer in serum than in plasma. The VN EC50 titer of 1:80 and 1:160
corresponded to 13.3 and 31.2 mg/L of RBD IgG in serum, respectively. Although these
values are not directly comparable with plasma since they do not correspond to the same
donors, they suggest that the VN activity of serum is lower than that of plasma, even if the
same concentration of RBD IgG is present. This result might suggest that additional factors
in plasma potentiate IgG VN activity. Alternatively, it could be that the different procedures
used to collect the plasma or serum may have influenced these results [44]. Anyhow, the
use of serum samples was aimed to confirm the utility of the ELISA test to quantify SARS-
CoV-2 RBD IgG in convalescent COVID-19 patients. Thus, the correlation with serum VN
activity is scientifically interesting albeit its clinical significance is limited since due to the
manufacturing process plasma is mostly used for passive immunization protocols.
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Similar to our analyses, other studies have found a good correlation between anti-
spike antibody titers and VN activity determined by other methods, although the number
of patients included in those studies was smaller than in ours [25,42,45,46].
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Importantly, our study presents two clear differences with all previous ones. First
we have established a quantitative RBD IgG ELISA test validated in two independent
large cohorts of patients, and second we have determined the RBD IgG concentration that
predicts the VN activity of convalescent plasma in vitro. The presence of high concentra-
tions of RBD IgG, and thus, high VN activity, depends on the severity of COVID-19, as
determined by hospitalization requirement and it is higher in male than in female patients.
The main limitation of our study is the variability in the number of days since the onset of
COVID-19 symptoms and plasma donation. In addition, it is not clear if our ELISA test
that has been developed using RBD antigens from the first viral strain isolated in China
in 2019 will efficiently detect IgG and predict the VN activity in samples from COVID-19
convalescent patients infected with new viral strains that present mutations in the RBD
sequence, such as the B1.1.7 (N501Y RBD), B1.1351 (N501Y, K417S, E484K RBD), and P1
(N501Y, K417T, E484K RBD) variants. Based on the most recent evidences it has been
found that the N501Y mutation only marginally affected the VN activity of plasma/serum
from COVID-19 patients or from patients immunized with the original spike mRNA vac-
cines [47–49]. In contrast, the E484K mutation seems to significantly affect the VN activity
of convalescent plasma or plasma from immunized individuals [47,48,50,51]. Notably, the
detection of RBD-specific antibodies in plasma from convalescent patients was not affected
if E484K RBD or wild-type RBD antigens [52] were used, suggesting that non-neutralizing
RBD-specific antibodies are detected by ELISA. Thus, our ELISA and others based on
wild-type RBD antigens might be able to detect mutated RBD IgG, albeit they might not be
able to predict the VN activity in the plasma/serum from individuals infected with the P1
or B1.1351 variants containing the E484K mutation. Pending further study confirming the
impact of different mutations on the VN activity of convalescent plasma from individuals
infected with different variants, it might be advisable to develop ELISA tests in which
different RBD sequences are used as antigens.
Preliminary clinical trials indicate that the selection of convalescent plasma donors
with a high level of VN antibodies is key for therapeutic success [20,23,25,28,53,54]. Thus,
pending of validation in future clinical trials and with the limitations described above,
our results indicate that the establishment of the SARS-CoV-2 RBD IgG concentration in
plasma samples would be very useful for optimal donor selection and effective passive
immunization in COVID-19.
4. Conclusions
The concentration of RBD-specific IgG predicts the viral neutralizing activity of con-
valescent plasma and serum against SARS-CoV-2. Quantitative anti-RBD IgG detection
systems might help to standardize and predict the efficacy of convalescent plasma against
SARS-CoV-2 and to optimize the creation of COVID-19 convalescent plasma biobanks to
treat the maximum number of patients with the highest efficacy.
Author Contributions: L.S. (Llipsy Santiago), I.U.-M., and M.A. designed the research studies,
conducted experiments, acquired and analyzed data, and wrote the first version of the manuscript;
A.M.G.-R., J.M.-L., E.M., S.R., A.R.-L., S.H., D.d.M., S.V.-S., A.G.-G., V.T., and E.L.-N. conducted
experiments; R.H.-G., N.A., R.B., P.M., A.F., J.M.D., L.S. (Laura Serrano), C.Y., and M.d.M.E.-B.
provided key reagents and human samples; E.M.G. designed the research studies; J.P. and J.R.P.-P.
conceived the original idea of the study, designed research studies, and coordinated the study. All
authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by grants from the Aragon Government (Fondo COVID-19),
the Fundacion Santander-Universidad de Zaragoza (Programa COVID-19), and the Instituto de
Salud Carlos III (COV20-00308). Work in the JP laboratory is funded by the FEDER (Fondo Europeo
de Desarrollo Regional, Gobierno de Aragón (Group B29_17R), Ministerio de Ciencia, Innovación
e Universidades (MCNU), Agencia Estatal de Investigación (SAF2017-83120-C2-1-R), Fundacion
Inocente Inocente, ASPANOA, and Carrera de la Mujer de Monzón. Work in the RH-G lab is funded
by ARAID, MCNU (CTQ2013-44367-C2-2-P, BFU2016-75633-P, and PID2019-105451GB-I00), and
Gobierno de Aragón (E34_R17 and LMP58_18) with FEDER (2014–2020) funds for “Building Europe
Biology 2021, 10, 208 12 of 14
from Aragón. LS was supported by a PhD fellowship (FPI) from the Ministry of Science, Innovation
and Universities. IUM, SH and SR were supported by a PhD fellowship from Aragon Government.
MA was supported by a post-doctoral fellowship “Juan de la Cierva-formación” from the Ministry of
Science, Innovation and Universities and DdM by a post-doctoral fellowship “Sara Borrell”. JP was
supported by the ARAID Foundation.
Institutional Review Board Statement: The study was conducted according to the guidelines of the
Declaration of Helsinki, and approved by the Ethics Committee of the Biobank of the Aragon Health
System (PT17/0015/0039).
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Data Availability Statement: The data presented in this study are available in article.
Acknowledgments: The authors would like to thank the Servicios Científico Técnicos del CIBA
(IACS-University of Zaragoza) and Servicio Apoyo Investigación (University of Zaragoza) for their
assistance during the experiments. We want to particularly acknowledge the patients and the Biobank
of the Aragon Health System (PT17/0015/0039) integrated in the Spanish National Biobanks Network
for their collaboration.
Conflicts of Interest: J.P. has received oncology research grant from BMS and speaker honorary from
Gilead and Fundación Miguel Servet. The rest of authors declare no conflicts of interest. Funders
have not had any role on study design, data collection, interpretation or analysis of data and results or
writing the MS. The funders have not had any role of the decision to submit this MS for publication.
References
1. Wu, F.; Zhao, S.; Yu, B.; Chen, Y.M.; Wang, W.; Song, Z.G.; Hu, Y.; Tao, Z.W.; Tian, J.H.; Pei, Y.Y.; et al. A new coronavirus
associated with human respiratory disease in China. Nature 2020, 579, 265–269. [CrossRef]
2. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. A Novel Coronavirus from
Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020, 382, 727–733. [CrossRef]
3. Peeri, N.C.; Shrestha, N.; Rahman, M.S.; Zaki, R.; Tan, Z.; Bibi, S.; Baghbanzadeh, M.; Aghamohammadi, N.; Zhang, W.; Haque, U.
The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: What lessons have
we learned? Int. J. Epidemiol. 2020, 49, 717–726. [CrossRef]
4. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical features of patients infected
with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 497–506. [CrossRef]
5. Xu, Z.; Shi, L.; Wang, Y.; Zhang, J.; Huang, L.; Zhang, C.; Liu, S.; Zhao, P.; Liu, H.; Zhu, L.; et al. Pathological findings of COVID-19
associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020, 8, 420–422. [CrossRef]
6. Grifoni, A.; Weiskopf, D.; Ramirez, S.I.; Mateus, J.; Dan, J.M.; Moderbacher, C.R.; Rawlings, S.A.; Sutherland, A.; Premkumar, L.;
Jadi, R.S.; et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed
Individuals. Cell 2020, 181, 1489–1501.e15. [CrossRef] [PubMed]
7. Weiskopf, D.; Schmitz, K.S.; Raadsen, M.P.; Grifoni, A.; Okba, N.M.A.; Endeman, H.; van den Akker, J.P.C.; Molenkamp, R.;
Koopmans, M.P.G.; van Gorp, E.C.M.; et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with
acute respiratory distress syndrome. Sci. Immunol. 2020, 5. [CrossRef]
8. Braun, J.; Loyal, L.; Frentsch, M.; Wendisch, D.; Georg, P.; Kurth, F.; Hippenstiel, S.; Dingeldey, M.; Kruse, B.; Fauchere, F.; et al.
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature 2020. [CrossRef]
9. Zhao, J.; Yuan, Q.; Wang, H.; Liu, W.; Liao, X.; Su, Y.; Wang, X.; Yuan, J.; Li, T.; Li, J.; et al. Antibody responses to SARS-CoV-2 in
patients of novel coronavirus disease 2019. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2020. [CrossRef]
10. Xiao, A.T.; Gao, C.; Zhang, S. Profile of specific antibodies to SARS-CoV-2: The first report. J. Infect. 2020, 81, 147–178. [CrossRef]
11. Robbiani, D.F.; Gaebler, C.; Muecksch, F.; Lorenzi, J.C.C.; Wang, Z.; Cho, A.; Agudelo, M.; Barnes, C.O.; Gazumyan, A.; Finkin, S.;
et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. Nature 2020. [CrossRef]
12. Odak, I.; Barros-Martins, J.; Bosnjak, B.; Stahl, K.; David, S.; Wiesner, O.; Busch, M.; Hoeper, M.M.; Pink, I.; Welte, T.; et al.
Reappearance of effector T cells is associated with recovery from COVID-19. EBioMedicine 2020, 57, 102885. [CrossRef]
13. Liu, J.; Li, S.; Liu, J.; Liang, B.; Wang, X.; Wang, H.; Li, W.; Tong, Q.; Yi, J.; Zhao, L.; et al. Longitudinal characteristics of
lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 2020, 55,
102763. [CrossRef] [PubMed]
14. Qin, C.; Zhou, L.; Hu, Z.; Zhang, S.; Yang, S.; Tao, Y.; Xie, C.; Ma, K.; Shang, K.; Wang, W.; et al. Dysregulation of Immune
Response in Patients with Coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2020,
71, 762–768. [CrossRef]
15. Zheng, M.; Gao, Y.; Wang, G.; Song, G.; Liu, S.; Sun, D.; Xu, Y.; Tian, Z. Functional exhaustion of antiviral lymphocytes in
COVID-19 patients. Cell. Mol. Immunol. 2020, 17, 533–535. [CrossRef] [PubMed]
Biology 2021, 10, 208 13 of 14
16. McCreary, E.K.; Pogue, J.M. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. Open Forum Infect.
Dis. 2020, 7, ofaa105. [CrossRef]
17. Fischer, J.C.; Zanker, K.; van Griensven, M.; Schneider, M.; Kindgen-Milles, D.; Knoefel, W.T.; Lichtenberg, A.; Tamaskovics, B.;
Djiepmo-Njanang, F.J.; Budach, W.; et al. The role of passive immunization in the age of SARS-CoV-2: An update. Eur. J. Med. Res.
2020, 25, 16. [CrossRef]
18. Kumar, S.; Sharma, V.; Priya, K. Battle against COVID-19: Efficacy of Convalescent Plasma as an emergency therapy. Am. J. Emerg.
Med. 2020. [CrossRef]
19. Perotti, C.; Baldanti, F.; Bruno, R.; Del Fante, C.; Seminari, E.; Casari, S.; Percivalle, E.; Glingani, C.; Musella, V.; Belliato, M.; et al.
Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter
trial. Haematologica 2020. [CrossRef]
20. Duan, K.; Liu, B.; Li, C.; Zhang, H.; Yu, T.; Qu, J.; Zhou, M.; Chen, L.; Meng, S.; Hu, Y.; et al. Effectiveness of convalescent plasma
therapy in severe COVID-19 patients. Proc. Natl. Acad. Sci. USA 2020, 117, 9490–9496. [CrossRef]
21. Liu, S.T.H.; Lin, H.M.; Baine, I.; Wajnberg, A.; Gumprecht, J.P.; Rahman, F.; Rodriguez, D.; Tandon, P.; Bassily-Marcus, A.; Bander,
J.; et al. Convalescent plasma treatment of severe COVID-19: A propensity score-matched control study. Nat. Med. 2020, 26,
1708–1713. [CrossRef]
22. Simonovich, V.A.; Burgos Pratx, L.D.; Scibona, P.; Beruto, M.V.; Vallone, M.G.; Vazquez, C.; Savoy, N.; Giunta, D.H.; Perez, L.G.;
Sanchez, M.D.L.; et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N. Engl. J. Med. 2021, 384,
619–629. [CrossRef] [PubMed]
23. Marano, G.; Vaglio, S.; Pupella, S.; Facco, G.; Catalano, L.; Liumbruno, G.M.; Grazzini, G. Convalescent plasma: New evidence for
an old therapeutic tool? Blood Transfus. 2016, 14, 152–157. [CrossRef] [PubMed]
24. Joyner, M.J.; Senefeld, J.W.; Klassen, S.A.; Mills, J.R.; Johnson, P.W.; Theel, E.S.; Wiggins, C.C.; Bruno, K.A.; Klompas, A.M.;
Lesser, E.R.; et al. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month
Experience. medRxiv Prepr. Serv. Health Sci. 2020. [CrossRef]
25. Li, L.; Zhang, W.; Hu, Y.; Tong, X.; Zheng, S.; Yang, J.; Kong, Y.; Ren, L.; Wei, Q.; Mei, H.; et al. Effect of Convalescent Plasma
Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial.
JAMA J. Am. Med Assoc. 2020, 324, 460–470. [CrossRef]
26. Gharbharan, A.; Jordans, C.C.E.; GeurtsvanKessel, C.; den Hollander, J.G.; Karim, F.; Mollema, F.P.N.; Stalenhoef, J.E.; Dofferhoff,
A.; Ludwig, I.; Koster, A.; et al. Convalescent Plasma for COVID-19. A randomized clinical trial. medRxiv Prepr. Serv. Health Sci.
2020. [CrossRef]
27. Avendano-Sola, C.; Ramos-Martinez, A.; Munez-Rubio, E.; Ruiz-Antoran, B.; Malo de Molina, R.; Torres, F.; Fernandez-Cruz, A.;
Callejas-Diaz, A.; Calderon, J.; Payares-Herrera, C.; et al. Convalescent Plasma for COVID-19: A multicenter, randomized clinical
trial. medRxiv Prepr. Serv. Health Sci. 2020. [CrossRef]
28. Agarwal, A.; Mukherjee, A.; Kumar, G.; Chatterjee, P.; Bhatnagar, T.; Malhotra, P.; Collaborators, P.T. Convalescent plasma in the
management of moderate covid-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial).
Bmj 2020, 371, m3939. [CrossRef]
29. Wu, L.P.; Wang, N.C.; Chang, Y.H.; Tian, X.Y.; Na, D.Y.; Zhang, L.Y.; Zheng, L.; Lan, T.; Wang, L.F.; Liang, G.D. Duration of
antibody responses after severe acute respiratory syndrome. Emerg. Infect. Dis. 2007, 13, 1562–1564. [CrossRef] [PubMed]
30. Payne, D.C.; Iblan, I.; Rha, B.; Alqasrawi, S.; Haddadin, A.; Al Nsour, M.; Alsanouri, T.; Ali, S.S.; Harcourt, J.; Miao, C.; et al.
Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus. Emerg. Infect. Dis. 2016, 22, 1824–1826.
[CrossRef]
31. Wajnberg, A.; Amanat, F.; Firpo, A.; Altman, D.R.; Bailey, M.J.; Mansour, M.; McMahon, M.; Meade, P.; Mendu, D.R.; Muellers, K.;
et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020. [CrossRef] [PubMed]
32. Dan, J.M.; Mateus, J.; Kato, Y.; Hastie, K.M.; Faliti, C.E.; Ramirez, S.I.; Frazier, A.; Yu, E.D.; Grifoni, A.; Rawlings, S.A.; et al.
Immunological memory to SARS-CoV-2 assessed for greater than six months after infection. bioRxiv Prepr. Serv. Biol. 2020.
[CrossRef]
33. Premkumar, L.; Segovia-Chumbez, B.; Jadi, R.; Martinez, D.R.; Raut, R.; Markmann, A.; Cornaby, C.; Bartelt, L.; Weiss, S.; Park, Y.;
et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in
SARS-CoV-2 patients. Sci. Immunol. 2020, 5. [CrossRef]
34. Liu, L.; Wang, P.; Nair, M.S.; Yu, J.; Rapp, M.; Wang, Q.; Luo, Y.; Chan, J.F.; Sahi, V.; Figueroa, A.; et al. Potent neutralizing
antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 2020, 584, 450–456. [CrossRef]
35. Amanat, F.; Stadlbauer, D.; Strohmeier, S.; Nguyen, T.H.O.; Chromikova, V.; McMahon, M.; Jiang, K.; Arunkumar, G.A.;
Jurczyszak, D.; Polanco, J.; et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 2020, 26,
1033–1036. [CrossRef]
36. Garcia-Garcia, A.; Ceballos-Laita, L.; Serna, S.; Artschwager, R.; Reichardt, N.C.; Corzana, F.; Hurtado-Guerrero, R. Structural
basis for substrate specificity and catalysis of alpha1,6-fucosyltransferase. Nat. Commun. 2020, 11, 973. [CrossRef]
37. Rambaut, A.; Holmes, E.C.; O’Toole, A.; Hill, V.; McCrone, J.T.; Ruis, C.; du Plessis, L.; Pybus, O.G. A dynamic nomenclature
proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat. Microbiol. 2020. [CrossRef] [PubMed]
38. Ramakrishnan, M.A. Determination of 50% endpoint titer using a simple formula. World J. Virol. 2016, 5, 85–86. [CrossRef]
[PubMed]
Biology 2021, 10, 208 14 of 14
39. Hou, H.; Wang, T.; Zhang, B.; Luo, Y.; Mao, L.; Wang, F.; Wu, S.; Sun, Z. Detection of IgM and IgG antibodies in patients with
coronavirus disease 2019. Clin. Transl. Immunol. 2020, 9, e01136. [CrossRef]
40. Liu, X.; Wang, J.; Xu, X.; Liao, G.; Chen, Y.; Hu, C.H. Patterns of IgG and IgM antibody response in COVID-19 patients. Emerg.
Microbes Infect. 2020, 9, 1269–1274. [CrossRef] [PubMed]
41. Li, L.; Tong, X.; Chen, H.; He, R.; Lv, Q.; Yang, R.; Zhao, L.; Wang, J.; Xu, H.; Liu, C.; et al. Characteristics and serological patterns
of COVID-19 convalescent plasma donors: Optimal donors and timing of donation. Transfusion 2020. [CrossRef]
42. Salazar, E.; Kuchipudi, S.V.; Christensen, P.A.; Eagar, T.N.; Yi, X.; Zhao, P.; Jin, Z.; Long, S.W.; Olsen, R.J.; Chen, J.; et al.
Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma.
bioRxiv Prepr. Serv. Biol. 2020. [CrossRef]
43. Manenti, A.; Maggetti, M.; Casa, E.; Martinuzzi, D.; Torelli, A.; Trombetta, C.M.; Marchi, S.; Montomoli, E. Evaluation of
SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum
samples. J. Med Virol. 2020. [CrossRef] [PubMed]
44. Morrison, B.J.; Martin, N.J.; Rehman, T.; Ewing, D.; Dewar, R.L.; Metcalf, J.; Sun, P.; Beigel, J.; Luke, T.C.; Raviprakash, K. Influence
of sample collection tube method, anticoagulant-containing plasma versus serum, on influenza virus hemagglutination inhibition
titer and microneutralization titer serological assays. BMC Health Serv. Res. 2018, 18, 651. [CrossRef] [PubMed]
45. Suthar, M.S.; Zimmerman, M.; Kauffman, R.; Mantus, G.; Linderman, S.; Vanderheiden, A.; Nyhoff, L.; Davis, C.; Adekunle, S.;
Affer, M.; et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. medRxiv Prepr. Serv. Health Sci. 2020.
[CrossRef]
46. Harvala, H.; Robb, M.; Watkins, N.; Ijaz, S.; Dicks, S.; Patel, M.; Supasa, P.; Dejnirattisai, W.; Liu, C.; Mongkolsapaya, J.; et al.
Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody
detection and their correlation with neutralising antibody levels. medRxiv Prepr. Serv. Health Sci. 2020. [CrossRef]
47. Collier, D.A.; De Marco, A.; Ferreira, I.A.T.M.; Meng, B.; Datir, R.; Walls, A.C.; Kemp, S.S.A.; Bassi, J.; Pinto, D.; Fregni, C.S.; et al.
SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodies. medRxiv Prepr. Serv. Health Sci. 2021. [CrossRef]
48. Wang, Z.; Schmidt, F.; Weisblum, Y.; Muecksch, F.; Barnes, C.O.; Finkin, S.; Schaefer-Babajew, D.; Cipolla, M.; Gaebler, C.;
Lieberman, J.A.; et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. bioRxiv Prepr. Serv. Biol. 2021.
[CrossRef]
49. Wu, K.; Werner, A.P.; Moliva, J.I.; Koch, M.; Choi, A.; Stewart-Jones, G.B.E.; Bennett, H.; Boyoglu-Barnum, S.; Shi, W.; Graham,
B.S.; et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv
Prepr. Serv. Biol. 2021. [CrossRef]
50. Andreano, E.; Piccini, G.; Licastro, D.; Casalino, L.; Johnson, N.V.; Paciello, I.; Monego, S.D.; Pantano, E.; Manganaro, N.; Manenti,
A.; et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv Prepr. Serv. Biol. 2020.
[CrossRef]
51. Greaney, A.J.; Starr, T.N.; Gilchuk, P.; Zost, S.J.; Binshtein, E.; Loes, A.N.; Hilton, S.K.; Huddleston, J.; Eguia, R.; Crawford, K.H.D.;
et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition.
bioRxiv Prepr. Serv. Biol. 2020. [CrossRef]
52. Wibmer, C.K.; Ayres, F.; Hermanus, T.; Madzivhandila, M.; Kgagudi, P.; Lambson, B.E.; Vermeulen, M.; van den Berg, K.; Rossouw,
T.; Boswell, M.; et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv Prepr. Serv.
Biol. 2021. [CrossRef]
53. Abolghasemi, H.; Eshghi, P.; Cheraghali, A.M.; Imani Fooladi, A.A.; Bolouki Moghaddam, F.; Imanizadeh, S.; Moeini Maleki, M.;
Ranjkesh, M.; Rezapour, M.; Bahramifar, A.; et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections:
Results of a multicenter clinical study. Transfus. Apher. Sci. Off. J. World Apher. Assoc. Off. J. Eur. Soc. Haemapheresis 2020, 102875.
[CrossRef] [PubMed]
54. Piechotta, V.; Chai, K.L.; Valk, S.J.; Doree, C.; Monsef, I.; Wood, E.M.; Lamikanra, A.; Kimber, C.; McQuilten, Z.; So-Osman, C.;
et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: A living systematic review. Cochrane
Database Syst. Rev. 2020, 7, CD013600. [CrossRef] [PubMed]
